Dapagliflozin Drug: An Extensive Review.

Abstract

DM type 2 is a prominent illness that is constantly progressing, which means that new treatment options need to be developed in order to enhance disease management. Introducing an innovative class of oral antihyperglycemic drugs known as SGLT2 inhibitors, of which DG is the second member of this group to be commercially available. When the cotransporter is blocked, it causes the kidneys to eliminate more glucose than usual, which ultimately results in lower amounts of glucose being present in the circulation. The primary transporter of glucose back into the bloodstream in the kidneys is an enzyme called SGLT2.As This drug belongs to new class of AHAs . Thus, this review was done to focus on this drug.